Status: Recruiting
EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1)
GRWD0715 is an orally administered, selective inhibitor of the Endoplasmic Reticulum Aminopeptidase 1 \[ERAP1\] enzyme being explored as a potential new treatment for axial spondyloarthritis (axSpA), a long term condition caused by inflammation predominantly affecting the sacroiliac joints (SIJs) and spine.
Participants needed: 140
Trial details
Phase: Phase 1, Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Grey Wolf TherapeuticsUpdated: Sep 18, 2026Locations: 16
Eligibility criteria
Healthy male and female subjects aged 18-55 years inclusive, at the Screening vi... [+16]
History or presence of any clinically significant findings in medical history, p... [+15]